A carregar...
Proteasome inhibition and its therapeutic potential in multiple myeloma
Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxi...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2990320/ https://ncbi.nlm.nih.gov/pubmed/21116326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S3419 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|